Edition:
United States

Biocartis Group NV (BCART.BR)

BCART.BR on Brussels Stock Exchange

12.30EUR
6:04am EDT
Change (% chg)

€0.10 (+0.82%)
Prev Close
€12.20
Open
€12.28
Day's High
€12.36
Day's Low
€12.22
Volume
5,738
Avg. Vol
68,578
52-wk High
€15.00
52-wk Low
€9.51

Latest Key Developments (Source: Significant Developments)

Biocartis Group Cash Position At End Q1 2018 Was 102 Million Euros
Thursday, 26 Apr 2018 01:00am EDT 

April 26 (Reuters) - Biocartis Group NV ::CASH POSITION AT END OF Q1 2018 AMOUNTED TO EUR 102M (UNAUDITED FIGURE).FULL YEAR GUIDANCE REITERATED.  Full Article

Biocartis FY Total Operating Income Up At 23.1 Million Euros
Thursday, 1 Mar 2018 01:06am EST 

March 1 (Reuters) - Biocartis Group Nv ::FY TOTAL OPERATING INCOME: EQUALED EUR 23.1M IN 2017 COMPARED TO EUR 13.8M IN 2016,.CASH AND CASH EQUIVALENTS AMOUNTED TO EUR 112.8M AS PER 31 DECEMBER 2017.EXPECTS CASH POSITION IN THE RANGE OF EUR 50MLN – EUR 60MLN BY 2018 YEAR END.FY NET LOSS EUR 42 MILLION VERSUS LOSS OF EUR 49.8 MILLION.FY OPERATING LOSS EUR 43.6 MILLION VERSUS LOSS EUR 50.2 MILLION YEAR AGO.  Full Article

The EU Provides Biocartis With Up To 24 Million Euros Debt For Infectious Disease Projects
Thursday, 1 Mar 2018 01:00am EST 

March 1 (Reuters) - Biocartis Group Nv ::REG-BIOCARTIS GROUP NV: EUROPEAN UNION PROVIDES BIOCARTIS WITH UP TO EUR 24M DEBT FINANCING FACILITY FOR INFECTIOUS DISEASE PROJECTS.THE DEBT FINANCING FACILITY CONSISTS OF TWO TRANCHES, EACH WITH A MINIMUM AMOUNT OF EUR 6 MLN‍​.FIRST TRANCHE IS TO BE DRAWN WITHIN 12 MONTHS.SECOND TRANCHE WITHIN 18 MONTHS FOLLOWING DISBURSEMENT OF FIRST TRANCHE.CO ENTITLED TO FORGO DRAWDOWNS ON FACILITY.  Full Article

Biocartis And Amgen Sign New Agreement
Tuesday, 9 Jan 2018 01:01am EST 

Jan 9 (Reuters) - Biocartis Group Nv ::REG-BIOCARTIS GROUP NV: BIOCARTIS AND AMGEN SIGN NEW COMPANION DIAGNOSTIC AGREEMENT FOR NOVEL ONCOLOGY COMPOUND.AGREEMENT AIMED AT DEVELOPMENT OF IDYLLA(TM) CDX BIOMARKER TESTS .FINANCIAL DETAILS ON NEW CDX AGREEMENT WITH AMGEN ARE NOT DISCLOSED..  Full Article

Biocartis And Amgen Sign Companion Diagnostic Agreement For Idylla(Tm) RAS Biomarker Tests
Monday, 4 Dec 2017 01:00am EST 

Dec 4 (Reuters) - BIOCARTIS GROUP NV ::BIOCARTIS AND AMGEN <<>> SIGN COMPANION DIAGNOSTIC AGREEMENT FOR IDYLLA(TM) RAS BIOMARKER TESTS.BIOCARTIS -WILL PURSUE A PREMARKET APPROVAL FOR IDYLLA KRAS MUTATION TEST AND IDYLLA NRAS-BRAF MUTATION TEST WITH FDA​.‍AMGEN WILL PROVIDE FINANCIAL AND OPERATIONAL SUPPORT TO BIOCARTIS FOR PMA PROCESS​.‍AIM OF AGREEMENT IS TO REGISTER IDYLLA RAS BIOMARKER TESTS WITH US FDA AS COMPANION DIAGNOSTIC TEST FOR AMGEN'S DRUG VECTIBIX(PANITUMUMAB).​.  Full Article

Bookrunner says Biocartis Group deal upsized to 80 mln euros From 60 mln euros base deal size‍​
Tuesday, 28 Nov 2017 02:13pm EST 

Nov 28 (Reuters) - :BLOCK TRADE- BIOCARTIS GROUP NV: BOOKRUNNER SAYS DEAL UPSIZED TO 80 MILLION EUROS FROM 60 MILLION EUROS BASE DEAL SIZE‍​.BLOCK TRADE- BIOCARTIS GROUP NV: BOOKRUNNER SAYS BOOKS ARE OVERSUBSCRIBED ON THE 80 MILLION EUROS DEAL SIZE.BLOCK TRADE- BIOCARTIS GROUP NV: BOOKRUNNER SAYS PRICE GUIDANCE OF 12.50 EUROS PER SHARE.BLOCK TRADE- BIOCARTIS GROUP NV: BOOKRUNNER SAYS BOOKS CLOSE AT 1830 UK TIME.  Full Article

Biocartis Share Offering Of Up To About 8.9 mln Shares ‍​- bookrunner
Tuesday, 28 Nov 2017 10:45am EST 

Nov 28 (Reuters) - Biocartis Group Nv's Bookrunner: :SAYS OFFERING OF UP TO ABOUT 8.9 MILLION SHARES ‍​.SAYS OFFERING DEAL SIZE ABOUT 60 MILLION EUROS‍​.  Full Article

Biocartis Launches Equity Placement
Tuesday, 28 Nov 2017 10:30am EST 

Nov 28 (Reuters) - Biocartis Group Nv ::REG-BIOCARTIS GROUP NV: BIOCARTIS LAUNCHES EQUITY PLACEMENT.‍EQUITY OFFERING TO RAISE AN AMOUNT OF APPROXIMATELY EUR 60 MILLION BY MEANS OF A PRIVATE PLACEMENT VIA AN ACCELERATED BOOKBUILD OFFERING​.‍POSSIBILITY TO INCREASE SIZE OF OFFERING TO UP TO 8,933,950 NEW SHARES IN TOTAL​.‍BOOKBUILDING PROCEDURE WILL COMMENCE IMMEDIATELY​.‍TRADING IN BIOCARTIS SHARES ON EURONEXT BRUSSELS WILL BE SUSPENDED DURING BOOKBUILDING PERIOD​.‍J.P. MORGAN, DEGROOF PETERCAM, KBC SECURITIES AND KEMPEN ARE ACTING AS JOINT BOOKRUNNERS IN OFFERING​.‍ENVISAGES USING NET PROCEEDS TO FUND EXPANSION OF IDYLLA TEST MENU AND APPLICATIONS​.‍TRADING IN STOCK IS EXPECTED TO RESUME FOLLOWING PUBLICATION OF RESULTS OF OFFERING​.  Full Article

Biocartis Group sees ‍2017 guidance reiterated
Thursday, 16 Nov 2017 01:00am EST 

Nov 16 (Reuters) - BIOCARTIS GROUP NV ::SEES ‍2017 GUIDANCE REITERATED​.‍CASH POSITION AT END OF Q3 2017 AMOUNTED TO APPROXIMATELY EUR 56 MILLION (UNAUDITED FIGURE)​.  Full Article

Genomic Health and Biocartis announce agreement to develop a breast cancer test
Wednesday, 13 Sep 2017 01:00am EDT 

Sept 13 (Reuters) - BIOCARTIS GROUP NV ::‍GENOMIC HEALTH AND BIOCARTIS ANNOUNCE AGREEMENT TO DEVELOP AN IDYLLA(TM) IVD ONCOTYPE DX(®) BREAST CANCER TEST TO BROADEN GLOBAL PATIENT ACCESS​.‍EXCLUSIVE AGREEMENT TO DEVELOP AN IVD VERSION OF ONCOTYPE DX BREAST RECURRENCE SCORE TEST ON BIOCARTIS' IDYLLA PLATFORM​.‍ONCOTYPE DX BREAST RECURRENCE SCORE TEST PLANNED FOR LAUNCH IN EUROPE BEGINNING WITH FRANCE AND GERMANY IN 2019​.‍AS PART OF AGREEMENT, GENOMIC HEALTH WILL MAKE A PAYMENT OF APPROXIMATELY $3.3 MILLION TO BIOCARTIS, WHICH IS EXPECTED TO BE EXPENSED IN Q3 OF 2017​.‍GENOMIC HEALTH CONTINUES TO EXPECT TO BE PROFITABLE FOR FULL YEAR 2017, EXCLUDING THESE TRANSACTION COSTS​.‍UPON COMMERCIALIZATION, GENOMIC HEALTH WILL MAKE ROYALTY PAYMENTS TO BIOCARTIS BASED ON NET SALES OF IVD TESTS DEVELOPED ON BIOCARTIS' IDYLLA PLATFORM​.  Full Article

BRIEF-Biocartis FY Total Operating Income Up At 23.1 Million Euros

* FY TOTAL OPERATING INCOME: EQUALED EUR 23.1M IN 2017 COMPARED TO EUR 13.8M IN 2016,